Vicapsys Life Sciences Inc VICP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.00
- Day Range
- $1.51–1.51
- 52-Week Range
- $0.42–14.00
- Bid/Ask
- $1.51 / $175.00
- Market Cap
- $48.43 Mil
- Volume/Avg
- 353 / 840
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
- Website
- https://www.vicapsys.com
Comparables
Valuation
|
Metric
|
VICP
|
ACLX
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 16.56 |
Price/Book Value | — | 8.61 | 4.82 |
Price/Sales | — | 27.51 | 8.60 |
Price/Cash Flow | — | 507.02 | 13.77 |
Price/Earnings
VICP
ACLX
PTGX
Financial Strength
|
Metric
|
VICP
|
ACLX
|
PTGX
|
|---|---|---|---|
Quick Ratio | 0.03 | 5.85 | 13.60 |
Current Ratio | 0.14 | 6.01 | 13.73 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
VICP
ACLX
PTGX
Profitability
|
Metric
|
VICP
|
ACLX
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −297.04% | −1.88% | 44.65% |
Return on Equity (Normalized) | — | −3.31% | 49.43% |
Return on Invested Capital (Normalized) | — | −7.10% | 44.16% |
Return on Assets
VICP
ACLX
PTGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vwnfqpywn | Gtqv | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ctkztcc | Sxjhdp | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fskzygcty | Thdtyhl | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zmkbhyhw | Tnvvknz | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Yglvtzxh | Qfnp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qkfvvgmxj | Cnvf | $29.2 Bil | |||
| Moderna Inc
MRNA
| Mhfjbtbp | Mcwg | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ktsltrxsj | Rlhw | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Grrqkcdsw | Kzbxxz | $13.2 Bil | |||
| Incyte Corp
INCY
| Wgkzxtnm | Gbdcdl | $13.0 Bil |
United States